Novartis AG Postfach 4002 Basel Switzerland |
January 27, 2016
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission on January 27, 2016.
Respectfully submitted, |
| |
|
| |
Novartis AG |
| |
|
| |
|
| |
/s/ FELIX R. EHRAT |
|
/s/ HARRY KIRSCH |
Felix R. Ehrat |
Harry Kirsch | |
General Counsel |
Chief Financial Officer | |
Novartis Group |
Novartis Group | |